Home

GMS Ventures & Investments

CIK 1804598 · last filed 2026-06-01

GMS Ventures & Investments is a corporate insider who has filed 12 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for OTLK, was dated Jun 1, 2026. Across all open-market trades the lifetime net is +$66.7M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $14.7M across reported positions. The firm reports its address in George Town. 13 SEC filings were submitted jointly with Ghiath M. Sukhtian.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$14.72M

Companies

2

Total Filings

12

Lifetime Open-Market Net

$66.72M

Filer Profile

Reported Address
C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
190 ELGIN AVENUE
GEORGE TOWN KY1-1104
Phone
962 6 582 7999
State of Incorporation
Cayman Islands
Related Filers
Ghiath M. Sukhtian — 13 joint filings, latest 2026-08-14
Faisal Ghiath Sukhtian — 1 joint filings, latest 2022-04-22
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
OTLK Director 22,092,068 $0.67 $14.72M $10.00M 7 2026-06-01
Outlook Therapeutics, Inc. (OTLKW) Delisted Director 27,982,529 $0.03 $839.5K $56.72M 5 2022-02-01

Recent Filings

12 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-01 OTLK Mixed +17,079,418 $10.00M EDGAR
2025-03-12 OTLK Exer (M) +6,917,142 $17.36M EDGAR
2025-01-22 OTLK Mixed — $0 EDGAR
2024-03-20 OTLK Grant (A) +4,611,428 $0 EDGAR
2022-12-29 OTLK Grant (A) +28,460,836 $25.00M EDGAR
2022-07-07 OTLK Other (J) +55,965,058 $0 EDGAR
2022-04-22 OTLK Other (J) +55,965,058 $0 EDGAR
2022-02-01 Outlook Therapeutics, Inc. (OTLKW) Delisted Other (J) +5,000,000 $6.25M EDGAR
2021-12-01 Outlook Therapeutics, Inc. (OTLKW) Delisted Buy (P) +32,000,000 $40.00M EDGAR
2021-02-11 Outlook Therapeutics, Inc. (OTLKW) Delisted Grant (A) +2,027,254 $2.03M EDGAR
Showing 1–10 of 12
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.